GERN · Geron Corporation

-

Please sign in to comment on GERN

1 Comment

Admin

4 years ago

Geron Corporation is currently in a long term downtrend where the price is trading 17.7% below its 200 day moving average.

From a valuation standpoint, the stock is 29.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1738.2.

Geron Corporation's total revenue sank by 70.8% to $50K since the same quarter in the previous year.

Its net income has increased by 18.2% to $-24M since the same quarter in the previous year.

Finally, its free cash flow fell by 20.8% to $-13M since the same quarter in the previous year.

Based on the above factors, Geron Corporation gets an overall score of 1/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US3741631036
Sector	Healthcare
Industry	Biotechnology

Market Cap	911M
Beta	0.66
PE Ratio	None
Target Price	4.125
Dividend Yield	None

ABOUT

Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN · Geron Corporation

-

Geron Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Geron Corporation using a moving average strategy